Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details)

v3.19.3
Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
NCI - equity (deficit) - beginning of period     $ (161,512)    
Net loss attributable to NCI $ (186,349) $ (32,431) (500,622) $ (113,631)  
NCI - equity (deficit) - end of period (520,356)   (520,356)   $ (161,512)
Noncontrolling Interest [Member]          
NCI - equity (deficit) - beginning of period     (161,512)
Investment in majority-owned subsidiary       1,812
Net loss attributable to NCI     (500,622)   (204,072)
Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation     141,778   40,748
NCI - equity (deficit) - end of period $ (520,356)   $ (520,356)   $ (161,512)